Immix Biopharma (IMMX) Stock Price

Immix Biopharma Price

NASDAQ·CLOSED
13.66USD+0.50 (+3.73 %)
Market closed

The consensus 12-month price target for Immix Biopharma is 12.24 USD, about 10.4% below where the stock trades today. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus. The stock trades about 597% above its 52-week low.

Immix Biopharma stock price

Volume
Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of Immix Biopharma over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Immix Biopharma stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Immix Biopharma's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Immix Biopharma Stock Price History
DateImmix Biopharma Price
8/21/202613.66 USD
8/20/202613.16 USD
8/19/202612.66 USD
8/18/202611.55 USD
8/14/202610.97 USD
8/13/202610.92 USD
8/12/202611.51 USD
8/10/202610.13 USD
8/7/20269.72 USD
8/6/202610.06 USD
8/5/20269.57 USD
8/4/20269.11 USD
8/3/20268.42 USD
7/31/20268.32 USD
7/30/20268.55 USD
7/29/20268.27 USD
7/27/20268.85 USD
7/23/20268.80 USD
7/22/20269.41 USD
7/21/20269.57 USD
7/20/20268.80 USD
7/17/202610.25 USD
7/16/202610.06 USD
7/15/202610.53 USD
7/14/202610.68 USD
7/13/202610.72 USD
7/10/202611.11 USD
7/9/202611.09 USD
7/8/202611.76 USD
7/7/202612.02 USD
7/6/202610.67 USD
7/2/202610.34 USD
7/1/20269.83 USD
6/30/202610.31 USD
6/29/202610.49 USD
6/26/20269.98 USD
6/25/20269.72 USD
6/24/202610.04 USD
6/23/20269.91 USD
6/22/20269.38 USD
6/18/20269.15 USD
6/17/20269.41 USD
6/16/20268.63 USD
6/15/20268.36 USD
6/12/20268.46 USD
6/11/20268.20 USD
6/10/20268.56 USD
6/9/20268.01 USD
6/8/20267.87 USD
6/5/20267.93 USD
6/4/20268.42 USD
6/3/20268.44 USD
6/2/20268.36 USD
6/1/20269.22 USD
5/29/20269.00 USD
5/28/20268.84 USD
5/27/20268.73 USD
5/26/20268.84 USD
5/22/20268.78 USD
5/21/20268.67 USD
5/20/20268.94 USD
5/19/20268.86 USD
5/18/20268.99 USD
5/15/20269.94 USD
5/14/202610.38 USD
5/13/202610.49 USD
5/12/202610.66 USD
5/11/20269.92 USD
5/8/20269.75 USD
5/7/20269.54 USD
5/6/202610.32 USD
5/5/20269.56 USD
5/4/20269.48 USD
5/1/20269.30 USD
4/30/20268.93 USD
4/29/20268.63 USD
4/28/20268.60 USD
4/27/20269.53 USD
4/24/20269.85 USD
4/23/202610.07 USD
4/22/202610.18 USD
4/21/20269.68 USD
4/20/202610.09 USD
4/17/202610.35 USD
4/16/20269.96 USD
4/15/202610.04 USD
4/14/20269.85 USD
4/13/20269.69 USD
4/10/20269.26 USD
4/9/20269.75 USD
4/8/20268.75 USD
4/7/20269.09 USD
4/6/20268.59 USD
4/2/20268.94 USD
4/1/20268.62 USD
3/31/20269.11 USD
3/30/20268.58 USD
3/27/20268.15 USD
3/26/20268.72 USD
3/25/20268.91 USD
3/24/20268.57 USD
3/23/20268.81 USD
3/20/20269.11 USD
3/19/20269.68 USD
3/18/20269.46 USD
3/17/202611.12 USD
3/16/202610.77 USD
3/13/202610.00 USD
3/12/202610.11 USD
3/11/202610.46 USD
3/10/202610.40 USD
3/9/202610.13 USD
3/6/20269.29 USD
3/5/20268.54 USD
3/4/20268.56 USD
3/3/20268.15 USD
3/2/20268.36 USD
2/27/20268.07 USD
2/26/20268.49 USD
2/25/20268.75 USD
2/24/20268.49 USD
2/23/20268.17 USD
2/20/20268.00 USD
2/19/20267.81 USD
2/18/20267.77 USD
2/17/20268.12 USD
2/13/20267.33 USD
2/12/20267.43 USD
2/11/20266.84 USD
2/10/20266.73 USD
2/9/20266.42 USD
2/6/20266.74 USD
2/5/20265.95 USD
2/4/20266.12 USD
2/3/20266.36 USD
2/2/20266.21 USD
1/30/20265.83 USD
1/29/20265.95 USD
1/28/20266.14 USD
1/27/20265.94 USD
1/26/20265.39 USD
1/23/20265.38 USD
1/22/20265.25 USD
1/21/20264.89 USD
1/20/20264.60 USD
1/16/20264.70 USD
1/15/20264.71 USD
1/14/20264.96 USD
1/13/20264.52 USD
1/12/20264.44 USD
1/9/20264.87 USD
1/8/20265.09 USD
1/7/20265.05 USD
1/6/20264.95 USD
1/5/20265.10 USD
1/2/20265.43 USD
12/31/20255.23 USD
12/30/20255.28 USD
12/29/20255.51 USD
12/26/20255.64 USD
12/24/20255.74 USD
12/23/20255.67 USD
12/22/20255.81 USD
12/19/20255.72 USD
12/18/20255.71 USD
12/17/20255.56 USD
12/16/20255.94 USD
12/15/20256.21 USD
12/12/20257.07 USD
12/11/20257.38 USD
12/10/20256.73 USD
12/9/20256.60 USD
12/8/20256.15 USD
12/5/20255.56 USD
12/4/20254.84 USD
12/3/20254.15 USD
12/2/20253.97 USD
12/1/20254.03 USD
11/28/20254.25 USD
11/26/20254.30 USD
11/25/20254.30 USD
11/24/20254.32 USD
11/21/20254.33 USD
11/20/20254.02 USD
11/19/20254.23 USD
11/18/20254.25 USD
11/17/20254.04 USD
11/14/20254.21 USD
11/13/20253.61 USD
11/12/20253.72 USD
11/11/20253.23 USD
11/10/20253.24 USD
11/7/20253.15 USD
11/6/20253.03 USD
11/5/20253.05 USD
11/4/20253.33 USD
11/3/20253.64 USD
10/31/20253.80 USD
10/30/20253.67 USD
10/29/20253.72 USD
10/28/20253.90 USD
10/27/20253.39 USD
10/24/20253.61 USD
10/23/20253.43 USD
10/22/20253.09 USD
10/21/20253.18 USD
10/20/20253.07 USD
10/17/20252.87 USD
10/16/20252.70 USD
10/15/20252.62 USD
10/14/20252.48 USD
10/13/20252.50 USD
10/10/20252.50 USD
10/9/20252.58 USD
10/8/20252.54 USD
10/7/20252.51 USD
10/6/20252.25 USD
10/3/20252.06 USD
10/2/20252.10 USD
10/1/20252.08 USD
9/30/20252.09 USD
9/29/20252.08 USD
9/26/20252.08 USD
9/25/20252.04 USD
9/24/20252.05 USD
9/23/20252.05 USD
9/22/20252.24 USD
9/19/20252.19 USD
9/18/20252.09 USD
9/17/20251.96 USD
9/16/20252.00 USD
9/15/20252.09 USD
9/12/20252.10 USD
9/11/20252.22 USD
9/10/20252.19 USD
9/9/20252.28 USD
9/8/20252.17 USD
9/5/20252.15 USD
9/4/20252.19 USD
9/3/20252.22 USD
9/2/20252.28 USD
8/29/20252.22 USD
8/28/20252.29 USD
8/27/20251.96 USD
8/26/20252.12 USD
8/25/20252.10 USD
Access this data via the Eulerpool API

Immix Biopharma Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
0.00 USD
-16.14 M USD
-15.43 M USD
Jan 1, 2024
0.00 USD
-22.67 M USD
-21.61 M USD
Jan 1, 2025
0.00 USD
-29.96 M USD
-29.44 M USD
Jan 1, 2026 (e)
0.00 USD
-31.14 M USD
-38.79 M USD
Jan 1, 2027 (e)
15.16 M USD
25.30 M USD
-47.13 M USD
Jan 1, 2028 (e)
178.63 M USD
87.06 M USD
-19.82 M USD
Jan 1, 2029 (e)
313.37 M USD
74.56 M USD
14.60 M USD
Jan 1, 2030 (e)
481.05 M USD
125.26 M USD
96.65 M USD

Immix Biopharma Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 23, 2026, 9:26 AM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
20192020202120222023202420252026e2027e2028e2029e2030e
-89.0015.00178.00313.00481.00
1,086.6775.8453.67
100.00100.00100.00100.00100.00
-89.00-89.00-89.00-89.00-89.00-89.00-89.00-89.0015.00178.00313.00481.00
-24.00-8.00-16.00-22.00-29.00-31.0025.0087.0074.00125.00
8.99166.6748.8823.6425.99
-1.00-24.00-8.00-15.00-21.00-29.00-38.00-47.00-19.0014.0096.00
2,300.00-66.6787.5040.0038.1031.0323.68-59.57-173.68585.71
3.007.587.5813.2319.9227.5438.2938.2938.2938.2938.2938.29
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Immix Biopharma generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Immix Biopharma retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Immix Biopharma's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Immix Biopharma has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Immix Biopharma's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Immix Biopharma stock margins

The Immix Biopharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Immix Biopharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Immix Biopharma.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
100.00 %
- %
- %
Jan 1, 2022
100.00 %
9.18 %
9.19 %
Jan 1, 2023
100.00 %
- %
- %
Jan 1, 2024
100.00 %
- %
- %
Jan 1, 2025
100.00 %
- %
- %
Jan 1, 2026 (e)
100.00 %
- %
- %
Jan 1, 2027 (e)
100.00 %
166.90 %
-310.96 %
Jan 1, 2028 (e)
100.00 %
48.74 %
-11.09 %

Immix Biopharma Stock Revenue, EBIT, Earnings per Share

The Immix Biopharma earnings per share therefore indicates how much revenue Immix Biopharma has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.00 USD
-3.19 USD
-3.22 USD
Jan 1, 2022
-6.77 USD
-0.62 USD
-0.62 USD
Jan 1, 2023
0.00 USD
-0.81 USD
-0.77 USD
Jan 1, 2024
0.00 USD
-0.82 USD
-0.78 USD
Jan 1, 2025
0.00 USD
-0.78 USD
-0.77 USD
Jan 1, 2026 (e)
0.00 USD
-0.81 USD
-0.74 USD
Jan 1, 2027 (e)
0.29 USD
0.66 USD
-0.90 USD
Jan 1, 2028 (e)
3.43 USD
2.27 USD
-0.38 USD

Immix Biopharma business model & stock analysis

Immix Biopharma Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Immix Biopharma Employees
Details
Date
Immix Biopharma Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Immix Biopharma Eulerpool Fair Value

Details

Fair Value Estimate

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Immix Biopharma historical P/E ratio, EBIT multiple, and P/S ratio

Immix Biopharma annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Immix Biopharma shares outstanding

The number of shares of Immix Biopharma was 38.29 M in 2025. This indicates how many shares Immix Biopharma is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
7.58 M Stocks
Jan 1, 2022
13.23 M Stocks
Jan 1, 2023
19.92 M Stocks
Jan 1, 2024
27.54 M Stocks
Jan 1, 2025
38.29 M Stocks
Jan 1, 2026 (e)
38.29 M Stocks
Jan 1, 2027 (e)
38.29 M Stocks
Jan 1, 2028 (e)
38.29 M Stocks

Current Immix Biopharma forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
85.71 % (6)
Hold
14.29 % (1)
Sell
0.00 % (0)
12M Price Target
12.24
Last Price
13.66
Currency
USD
12M Return Potential
-10.40 %
LTM Return
0 %

Immix Biopharma Analyst Rating Actions

DateFirmActionRatingReliability
8/11/2026
Morgan Stanley
Morgan Stanley
MaintainedOverweight51
8/10/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy
5/22/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy
3/30/2026
Mizuho
Mizuho
MaintainedOutperform31
3/30/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy
3/27/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy
3/27/2026
Citizens
Citizens
MaintainedMarket Outperform
12/9/2025
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy
9/12/2025
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy
6/4/2025
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Immix Biopharma Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/6/2026-0.18USD-0.00USD-2026 Q2
5/6/2026-0.21USD-0.00USD-2026 Q1
3/23/2026-0.16USD-0.00USD-2025 Q4
8/11/2025-0.16USD--USD-2025 Q2
11/9/2024-0.16USD-0.00USD-2024 Q3

Immix Biopharma shareholder structure

% Name
2.18780%
Rachman (Ilya M)
Rachman (Ilya M)
1.62991%
Bleichroeder LP
Bleichroeder LP
1.33948%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
1.12300%
Morris (Gabriel S)
Morris (Gabriel S)
0.80909%
Chang (Nancy T)
Chang (Nancy T)
0.30895%
Geode Capital Management, L.L.C.
Geode Capital Management, L.L.C.

Immix Biopharma Beneficial Ownership Filings (SEC 13D/G)

Free Float
79.8%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
19.99%
Yekaterina Chudnovsky
Yekaterina Chudnovsky
SEC ↗
19.99%
GKCC, LLC
GKCC, LLC
SEC ↗
13.00%
JANUS HENDERSON GROUP PLC
JANUS HENDERSON GROUP PLC
SEC ↗
6.97%
Saturn V Capital Management LP
Saturn V Capital Management LP
SEC ↗
5.80%
Identification Nos. of above persons (.
Identification Nos. of above persons (.
SEC ↗
5.80%
27-4413262
27-4413262
SEC ↗
5.28%
Murchinson
    Ltd.
Murchinson Ltd.
SEC ↗
5.28%
Marc
    Bistricer
Marc Bistricer
SEC ↗
3.30%
Millennium Management LLC
Millennium Management LLC
SEC ↗
1.60%
Altium Growth GP, LLC
Altium Growth GP, LLC
SEC ↗

Immix Biopharma Executives and Management Board

11 members · avg. age 58 · 45 % women

IR

Dr. Ilya Rachman (53)

Chairman of the Board, Chief Executive Officer · since 2012

1.27 M USD

Management

GM

Mr. Gabriel Morris (39)

Chief Financial Officer, Director · since 2021

1.27 M USD
GR

Dr. Graham Ross (65)

Acting Chief Medical Officer, Head - Clinical Development

88,593.00 USD
VT

Dr. Vladimir Torchilin (78)

Scientific Co-Founder

Board of Directors

HA

Ms. Helen Adams (66)

Lead Independent Director

124,226.00 USD
JB

Ms. Jane Buchan (61)

Independent Director

112,226.00 USD
MM

Dr. Magda Marquet (66)

Independent Director

105,726.00 USD
CN

Mr. Carey Ng (46)

Independent Director

99,226.00 USD
JH

Mr. Jason Hsu (51)

Independent Director

93,976.00 USD
YC

Ms. Yekaterina Chudnovsky (40)

Independent Director

93,726.00 USD

Frequently asked questions about Immix Biopharma

Analysts currently set an average price target of 12.24 USD for the Immix Biopharma stock (median: 12.24 USD), implying -10.4 % versus the latest price. The consensus is based on 7 analyst ratings.

7 analysts currently rate the Immix Biopharma stock: 6 recommend buying, 1 holding and 0 selling.

Converted at the current exchange rate, the Immix Biopharma share trades at 11.69 EUR (13.66 USD).

The Immix Biopharma share (IMMX) is listed on 1 stock exchanges, including: NASDAQ (IMMX).

No history available for Immix Biopharma.

The revenue cannot currently be calculated for Immix Biopharma.

The expected profit of Immix Biopharma is -38.79 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Immix Biopharma is currently -13.48. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Immix Biopharma stock.

The P/S cannot be calculated for Immix Biopharma currently.

The Eulerpool Quality Score for Immix Biopharma is 2/10.

The ISIN of Immix Biopharma is US45258H1068. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Immix Biopharma is IMMX. The ticker symbol is used to trade Immix Biopharma shares on the stock exchange.

Immix Biopharma paid dividends every year for the past 0 years.

Immix Biopharma is assigned to the 'Health' sector.

The dividends of Immix Biopharma are distributed in USD.